低剂量氯胺酮与危重症患者幻觉的关联:一项目标试验模拟
该研究采用目标试验模拟方法,基于澳大利亚墨尔本一家大学附属ICU 2016年6月至2021年4月的回顾性数据,纳入7514例患者,其中625例(8%)接受低剂量氯胺酮,起始时间为入ICU后中位0(0-1)天,平均日剂量0.11(0.08-0.15)mg/kg/h。低剂量氯胺酮组30天内幻觉发生率为26%,未暴露组为7%(p<0.001),且首次幻觉出现更早(入ICU后2[1-3]天 vs 3[1-7]天;p<0.001)。校正基线与时间依赖混杂因素后,低剂量氯胺酮与30天内幻觉风险升高相关(OR 6.46[95%CI 5.17-8.07];p<0.001),参数g公式结果一致。作者结论为二者强关联,但因观察性设计与残余混杂风险需谨慎解读。
要点
- 在7514例ICU患者中,625例(8%)接受低剂量氯胺酮,起始中位时间为入ICU后0(0-1)天,平均日剂量0.11(0.08-0.15)mg/kg/h。
- 低剂量氯胺酮组30天内幻觉发生率26%,未暴露组7%(p<0.001);校正混杂后OR 6.46(95%CI 5.17-8.07;p<0.001)。
- 首次幻觉出现时间:低剂量氯胺酮组为入ICU后2(1-3)天,未暴露组为3(1-7)天(p<0.001)。
- 参数g公式证实了主要分析结果;作者提示因观察性设计与残余混杂风险,结论需谨慎解读。
适用人群与场景
- 澳大利亚墨尔本一家大学附属ICU的危重症患者,数据时段为2016年6月至2021年4月,共7514例。
研究设计与关键结果
- 回顾性研究,采用目标试验模拟、边际结构模型与参数g公式,评估低剂量氯胺酮对ICU患者幻觉发生的影响。
- 7514例患者中625例(8%)接受低剂量氯胺酮,起始中位时间为入ICU后0(0-1)天,平均日剂量0.11(0.08-0.15)mg/kg/h。
- 低剂量氯胺酮组30天内幻觉发生率26%,未暴露组7%(p<0.001);首次幻觉出现时间低剂量氯胺酮组为入ICU后2(1-3)天,未暴露组为3(1-7)天(p<0.001)。
- 校正基线与时间依赖混杂因素后,低剂量氯胺酮与30天内幻觉风险升高相关(OR 6.46[95%CI 5.17-8.07];p<0.001),参数g公式结果一致。
证据类型、等级与局限
- 证据类型:回顾性研究,采用目标试验模拟方法。
- 局限:原文指出研究为观察性研究,存在残余混杂风险,结论需谨慎解读。
对床旁实践的改变
- 作者认为,ICU患者中低剂量氯胺酮与幻觉风险升高强烈相关;但因研究为观察性设计且存在残余混杂风险,该结果需谨慎解读,原文未据此给出用药推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Ketamine use is a potentially modifiable risk factor for hallucinations. We aimed to use target trial emulation to investigate the association between low-dose ketamine and development of hallucinations in critically ill patients in the intensive care unit (ICU).
METHODS: Retrospective study using data from a university affiliated ICU in Melbourne, Australia. Application of marginal structural models and parametric g-formulas to assess the impact of low-dose ketamine on the development of hallucinations.
RESULTS: We studied 7514 patients from June 2016 to April 2021. Of these, 625 patients (8%) received low-dose ketamine, beginning at a median of 0 (0-1) days from ICU admission and at a mean daily dose of 0.11 (0.08-0.15) mg/kg/h. Low-dose ketamine treated patients had a higher rate of hallucinations within 30 days of ICU admission (26% vs. 7%; p < 0.001) and the first episode of hallucination occurred earlier than in unexposed patient (2 [1-3] vs. 3 [1-7] days from ICU admission; p < 0.001). After adjustment for baseline and time-dependent confounders, low-dose ketamine was associated with a higher risk of hallucinations within 30 days (OR, 6.46 [95% CI 5.17-8.07]; p < 0.001). These findings were confirmed with parametric g-formulas.
CONCLUSIONS: In ICU patients, low-dose ketamine was strongly associated with an increased risk of hallucinations. However, these findings should be interpreted with caution due to the observational nature of the study and the risk of residual confounding.
参考来源
- Serpa Neto A, Young M, Chan JW, et al. Association of low-dose ketamine with hallucinations in critically ill patients: a target trial emulation. Intensive Care Med. 2025. PMID: 40323454. doi:10.1007/s00134-025-07926-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。